Lenvatinib plus pembrolizumab for patients with previously treated, advanced, triple‐negative breast cancer: Results from the triple‐negative breast cancer cohort of …
HC Chung, E Saada‐Bouzid, F Longo, E Yanez… - Cancer, 2024 - Wiley Online Library
Background Novel treatments are needed for patients with advanced, triple‐negative breast
cancer (TNBC) that progresses or recurs after first‐line treatment with chemotherapy. The …
cancer (TNBC) that progresses or recurs after first‐line treatment with chemotherapy. The …
Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?
M Yeghaian, TM Tareco Bucho, M de Bruin… - Journal of Cancer …, 2024 - Springer
Purpose In this study, we aimed to evaluate the potential of routine blood markers, serum
tumour markers and their combination in predicting RECIST-defined progression in patients …
tumour markers and their combination in predicting RECIST-defined progression in patients …
The ULS23 Challenge: a Baseline Model and Benchmark Dataset for 3D Universal Lesion Segmentation in Computed Tomography
MJJ de Grauw, ET Scholten, EJ Smit, M Rutten… - arXiv preprint arXiv …, 2024 - arxiv.org
Size measurements of tumor manifestations on follow-up CT examinations are crucial for
evaluating treatment outcomes in cancer patients. Efficient lesion segmentation can speed …
evaluating treatment outcomes in cancer patients. Efficient lesion segmentation can speed …
[HTML][HTML] Reproducing RECIST lesion selection via machine learning: Insights into intra and inter-radiologist variation
TMT Bucho, L Petrychenko, MA Abdelatty… - European journal of …, 2024 - Elsevier
Abstract Background The Response Evaluation Criteria in Solid Tumors (RECIST) aims to
provide a standardized approach to assess treatment response in solid tumors. However …
provide a standardized approach to assess treatment response in solid tumors. However …
Urine Liquid Biopsies via Highly Integrated Digital PCR System for Accurate Detection of Bladder Cancer
Y Zhang, M Xu, Z Wu, F Yang, L Zhang, Y Liu… - Advanced … - Wiley Online Library
Bladder cancer (BC) is a prevalent urological tumor with high recurrence rates, requiring
long‐term monitoring. Although cystoscopy is the primary diagnostic method, its …
long‐term monitoring. Although cystoscopy is the primary diagnostic method, its …
[HTML][HTML] Биомаркеры оценки результатов полихимиотерапии больных адренокортикальным раком на основании исследования стероидных профилей мочи …
ЛИ Великанова, НВ Ворохобина… - Альманах …, 2024 - cyberleninka.ru
Обоснование. Эффективность полихимиотерапии (ПХТ) в лечении
адренокортикального рака (АКР) оценивается визуализирующими методами …
адренокортикального рака (АКР) оценивается визуализирующими методами …
Biomarkers for assessment of the polychemotherapy results in patients with adrenocortical cancer based on gas chromatography-mass spectrometry studies of urine …
LI Velikanova, NV Vorokhobina… - Almanac of Clinical …, 2024 - almclinmed.ru
Background: The effectiveness of polychemotherapy (PCT) for adrenocortical cancer (ACC)
is assessed by imaging tests with the RECIST 1.1 criteria. However, the presence of …
is assessed by imaging tests with the RECIST 1.1 criteria. However, the presence of …